The association between the CCDC88A gene polymorphism at rs1437396 and alcohol use disorder, with or without major depression disorder
Author:
Bonea Maria1ORCID, Coroama Constantin-Ionut2, Popp Radu Anghel3, Miclutia Ioana Valentina1
Affiliation:
1. 1 Iuliu Hatieganu University of Medicine and Pharmacy, Department of Neurosciences – Psychiatry , Cluj-Napoca , Romania 2. 2 Ion Chiricuta Oncology Institute , Cluj-Napoca , Romania 3. 3 Iuliu Hatieganu University of Medicine and Pharmacy, Department of Medical Genetics , Cluj-Napoca , Romania
Abstract
Abstract
Girdin is a protein involved in neuronal migration and hippocampal development. It is encoded by the coiled-coil domain-containing 88A (CCDC88A) gene, located on the short arm of chromosome 2 (2p). The CCDC88A gene is modulated by the intergenic single-nucleotide polymorphism (SNP) of the rs1437396, situated 9.5 kb downstream from its transcription stop site. As recent genome-wide research has associated the T allele of the SNP with increased risk of alcohol use disorder (AUD), we wanted to validate this finding in an independent cohort and to test further for an association with comorbid major depressive disorder (MDD). The study included 226 AUD patients (AUD group), 53 patients with comorbid MDD, and 391 controls selected randomly. The participants were genotyped for the rs1437396 polymorphism using the real-time polymerase chain reaction. The association between the rs1437396 polymorphism and increased risk of AUD and AUD+MDD was tested with logistic regression. Our results show significantly higher frequency of the T risk allele in the AUD group (p=0.027) and even higher in the AUD+MDD group (p=0.016). In conclusion, this is the first study that has validated the association between the rs1437396 polymorphism of the CCDC88A gene and AUD with or without MDD. Studies on larger samples of patients are needed to further investigate the mechanism of this association.
Publisher
Walter de Gruyter GmbH
Subject
Public Health, Environmental and Occupational Health,Toxicology
Reference41 articles.
1. Castillo-Carniglia A, Keyes KM, Hasin DS, Cerdá M. Psychiatric comorbidities in alcohol use disorder. Lancet Psychiat 2019;6:1068–80. doi: 10.1016/S2215-0366(19)30222-6 2. Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, Whiteford H, Leung J, Naghavi M, Griswold M, Rehm J, Hall W, Sartorius B, Scott J, Vollset SE, Knudsen AK, Haro JM, Patton G, Kopec J, Carvalho Malta D, Topor-Madry R, McGrath J, Haagsma J, Allebeck P, Phillips M, Salomon J, Hay S, Foreman K, Lim S, Mokdad A, Smith M, Gakidou E, Murray C, Vos T. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiat 2018;5:987–1012. doi: 10.1016/S2215-0366(18)30337-7 3. Edenberg HJ, Foroud T. Genetics and alcoholism. Nat Rev Gastroenterol Hepatol 2013;10:487–94. doi: 10.1038/nrgastro.2013.86 4. Heath AC, Whitfield JB, Martin NG, Pergadia ML, Goate AM, Lind PA, McEvoy BP, Schrage AJ, Grant JD, Chou YL, Zhu R, Henders AK, Medland SE, Gordon SD, Nelson EC, Agrawal A, Nyholt DR, Bucholz KK, Madden PA, Montgomery GW. A quantitative-trait genome-wide association study of alcoholism risk in the community: findings and implications. Biol Psychiatry 2012;70:513–8. doi: 10.1016/j.biopsych.2011.02.028 5. Deak JD, Miller AP, Gizer IR. Genetics of alcohol use disorder: a review. Curr Opin Psychol 2019;27:56–61. doi: 10.1016/j.copsyc.2018.07.012
|
|